Abstract
Scandium radioisotopes are increasingly considered viable radiolabels for targeted molecular imaging (Sc-43, Sc-44) and therapy (Sc-47). Significant technological advances have increased the quantity and quality of available radioscandium in the past decade, motivated in part by the chemical similarity of scandium to therapeutic radionuclides like Lu-177. The production and radiochemical isolation techniques applied to scandium radioisotopes are reviewed, focusing on charged particle and electron linac initiated reactions and using calcium and titanium as starting materials.
Keywords: Scandium, cross-section, therapeutic radioisotopes, theranostics, PET, radioisotope production, radiochemical separation, radiometal, SPECT, radiolabeling.
Graphical Abstract
Current Radiopharmaceuticals
Title:Accelerator Production of Scandium Radioisotopes: Sc-43, Sc-44, and Sc-47
Volume: 14 Issue: 4
Author(s): Margarita Chernysheva, Shaun C. Loveless, Tom Brossard, Kaelyn Becker, Shelbie Cingoranelli, Eduardo Aluicio-Sarduy, Jeongseong Song, Paul Ellison, Jerry Nolen, David A. Rotsch, Suzanne E. Lapi and Jonathan W. Engle*
Affiliation:
- Departments of Medical Physics and Radiology, University of Wisconsin Madison B1303 WIMR Cyclotron Laboratory, 1111 Highland Avenue, Madison WI 53705,United States
Keywords: Scandium, cross-section, therapeutic radioisotopes, theranostics, PET, radioisotope production, radiochemical separation, radiometal, SPECT, radiolabeling.
Abstract: Scandium radioisotopes are increasingly considered viable radiolabels for targeted molecular imaging (Sc-43, Sc-44) and therapy (Sc-47). Significant technological advances have increased the quantity and quality of available radioscandium in the past decade, motivated in part by the chemical similarity of scandium to therapeutic radionuclides like Lu-177. The production and radiochemical isolation techniques applied to scandium radioisotopes are reviewed, focusing on charged particle and electron linac initiated reactions and using calcium and titanium as starting materials.
Export Options
About this article
Cite this article as:
Chernysheva Margarita , Loveless C. Shaun , Brossard Tom , Becker Kaelyn , Cingoranelli Shelbie , Aluicio-Sarduy Eduardo , Song Jeongseong , Ellison Paul , Nolen Jerry , Rotsch A. David , Lapi E. Suzanne and Engle W. Jonathan *, Accelerator Production of Scandium Radioisotopes: Sc-43, Sc-44, and Sc-47, Current Radiopharmaceuticals 2021; 14 (4) . https://dx.doi.org/10.2174/1874471014999210112205535
DOI https://dx.doi.org/10.2174/1874471014999210112205535 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry Polyploidy: The Link Between Senescence and Cancer
Current Pharmaceutical Design Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario
Current Topics in Medicinal Chemistry Spectrophotometric Methodologies Applied for Determination of Pharmaceuticals
Current Analytical Chemistry Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses
Recent Patents on Anti-Cancer Drug Discovery Targeting Tumor-Associated Antigens to the MHC Class I Presentation Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Pharmaceutical Biotechnology Biological and Chemical Diversity of Coral-Derived Microorganisms
Current Medicinal Chemistry Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules
Current Drug Targets Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Combined Therapies of Bone Disease with Bisphosphonates
Current Pharmaceutical Design Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets Tumor-Targeted Drug Delivery with Aptamers
Current Medicinal Chemistry The Role of Iron Chelation in Cancer Therapy
Current Medicinal Chemistry Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeted – Therapy and Imaging Response: A New Paradigm For Clinical Evaluation?
Reviews on Recent Clinical Trials